| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 14 | 2025 | 208 | 2.380 |
Why?
|
| Influenza Vaccines | 12 | 2025 | 99 | 2.230 |
Why?
|
| Hospitalization | 34 | 2025 | 1364 | 2.010 |
Why?
|
| Sepsis | 19 | 2024 | 289 | 1.960 |
Why?
|
| Intensive Care Units | 24 | 2024 | 406 | 1.920 |
Why?
|
| Respiration, Artificial | 20 | 2023 | 296 | 1.760 |
Why?
|
| Noninvasive Ventilation | 7 | 2021 | 69 | 1.240 |
Why?
|
| Protein C | 10 | 2012 | 26 | 1.230 |
Why?
|
| Hospital Mortality | 18 | 2025 | 877 | 1.000 |
Why?
|
| Respiratory Insufficiency | 7 | 2021 | 155 | 1.000 |
Why?
|
| Critical Care | 12 | 2024 | 396 | 0.990 |
Why?
|
| Vaccination | 17 | 2025 | 362 | 0.970 |
Why?
|
| Middle Aged | 79 | 2025 | 17613 | 0.960 |
Why?
|
| United States | 56 | 2025 | 7843 | 0.950 |
Why?
|
| Adult | 76 | 2025 | 16824 | 0.950 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 209 | 0.940 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 223 | 0.930 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2025 | 35 | 0.870 |
Why?
|
| Aged | 62 | 2025 | 14447 | 0.830 |
Why?
|
| Humans | 132 | 2025 | 63445 | 0.820 |
Why?
|
| Decision Making | 8 | 2024 | 407 | 0.740 |
Why?
|
| Male | 77 | 2025 | 29891 | 0.710 |
Why?
|
| Female | 80 | 2025 | 32880 | 0.710 |
Why?
|
| Acute Lung Injury | 8 | 2019 | 45 | 0.670 |
Why?
|
| Professional-Family Relations | 7 | 2024 | 88 | 0.630 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2025 | 90 | 0.600 |
Why?
|
| Shock, Septic | 4 | 2018 | 86 | 0.570 |
Why?
|
| Critical Illness | 11 | 2023 | 321 | 0.560 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2018 | 58 | 0.540 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 4 | 2025 | 28 | 0.540 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 62 | 0.520 |
Why?
|
| Pulmonary Embolism | 1 | 2018 | 173 | 0.480 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2025 | 22 | 0.460 |
Why?
|
| Recombinant Proteins | 7 | 2012 | 702 | 0.440 |
Why?
|
| Young Adult | 17 | 2025 | 4694 | 0.440 |
Why?
|
| Betacoronavirus | 3 | 2020 | 182 | 0.440 |
Why?
|
| Liver Diseases | 3 | 2008 | 156 | 0.430 |
Why?
|
| Fluid Therapy | 5 | 2023 | 47 | 0.430 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2014 | 13 | 0.420 |
Why?
|
| Treatment Outcome | 25 | 2025 | 5680 | 0.420 |
Why?
|
| Communication | 5 | 2019 | 572 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2017 | 712 | 0.410 |
Why?
|
| Adolescent | 21 | 2025 | 6245 | 0.400 |
Why?
|
| Pandemics | 10 | 2023 | 671 | 0.390 |
Why?
|
| Case-Control Studies | 10 | 2025 | 1119 | 0.380 |
Why?
|
| Blood Group Incompatibility | 1 | 2012 | 10 | 0.380 |
Why?
|
| Vital Signs | 1 | 2012 | 12 | 0.380 |
Why?
|
| Blood Volume | 1 | 2012 | 41 | 0.370 |
Why?
|
| Transfusion Reaction | 1 | 2012 | 46 | 0.370 |
Why?
|
| Anti-Infective Agents | 2 | 2010 | 150 | 0.360 |
Why?
|
| Length of Stay | 8 | 2021 | 812 | 0.350 |
Why?
|
| Prospective Studies | 15 | 2025 | 3293 | 0.340 |
Why?
|
| Influenza B virus | 3 | 2025 | 9 | 0.340 |
Why?
|
| Proxy | 3 | 2019 | 14 | 0.340 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 21 | 0.340 |
Why?
|
| Personnel, Hospital | 2 | 2020 | 44 | 0.340 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 327 | 0.330 |
Why?
|
| Aged, 80 and over | 20 | 2025 | 5462 | 0.330 |
Why?
|
| Pregnancy Complications | 2 | 2005 | 378 | 0.330 |
Why?
|
| Patient Preference | 3 | 2024 | 84 | 0.330 |
Why?
|
| Retrospective Studies | 16 | 2021 | 6658 | 0.320 |
Why?
|
| Antiviral Agents | 2 | 2025 | 324 | 0.300 |
Why?
|
| Multiple Organ Failure | 5 | 2018 | 44 | 0.300 |
Why?
|
| Bias | 3 | 2024 | 112 | 0.300 |
Why?
|
| Hemodynamics | 4 | 2008 | 250 | 0.300 |
Why?
|
| Lung | 3 | 2018 | 956 | 0.300 |
Why?
|
| HELLP Syndrome | 2 | 2005 | 3 | 0.290 |
Why?
|
| Severity of Illness Index | 10 | 2022 | 1553 | 0.290 |
Why?
|
| Pneumonia | 5 | 2021 | 291 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2005 | 205 | 0.280 |
Why?
|
| Logistic Models | 9 | 2021 | 1276 | 0.270 |
Why?
|
| Vasoconstrictor Agents | 3 | 2023 | 70 | 0.260 |
Why?
|
| Pre-Eclampsia | 2 | 2005 | 71 | 0.260 |
Why?
|
| Fatty Liver | 2 | 2005 | 108 | 0.260 |
Why?
|
| Physicians | 3 | 2022 | 470 | 0.250 |
Why?
|
| Hospitals, Teaching | 2 | 2018 | 106 | 0.250 |
Why?
|
| Cohort Studies | 11 | 2024 | 2570 | 0.250 |
Why?
|
| Influenza A virus | 2 | 2025 | 123 | 0.250 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2021 | 698 | 0.230 |
Why?
|
| Oseltamivir | 1 | 2025 | 35 | 0.230 |
Why?
|
| Shock | 2 | 2008 | 33 | 0.230 |
Why?
|
| RNA, Messenger | 7 | 2023 | 1537 | 0.230 |
Why?
|
| Vaccines, Synthetic | 5 | 2022 | 78 | 0.230 |
Why?
|
| Age Factors | 6 | 2025 | 1558 | 0.220 |
Why?
|
| Glucocorticoids | 2 | 2015 | 188 | 0.210 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 108 | 0.210 |
Why?
|
| Asthma | 3 | 2021 | 459 | 0.210 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 23 | 0.210 |
Why?
|
| Venous Thromboembolism | 1 | 2025 | 149 | 0.200 |
Why?
|
| Seasons | 4 | 2025 | 134 | 0.200 |
Why?
|
| Pulmonary Circulation | 1 | 2003 | 27 | 0.200 |
Why?
|
| Hypotension | 2 | 2023 | 50 | 0.200 |
Why?
|
| Prognosis | 9 | 2023 | 1748 | 0.200 |
Why?
|
| Tidal Volume | 2 | 2019 | 41 | 0.200 |
Why?
|
| Neurologic Examination | 1 | 2003 | 53 | 0.200 |
Why?
|
| Goals | 1 | 2023 | 90 | 0.200 |
Why?
|
| Bacterial Infections | 1 | 2024 | 149 | 0.190 |
Why?
|
| Outpatients | 2 | 2021 | 142 | 0.190 |
Why?
|
| Comorbidity | 7 | 2017 | 1120 | 0.190 |
Why?
|
| Treatment Failure | 6 | 2021 | 201 | 0.190 |
Why?
|
| Family | 3 | 2024 | 237 | 0.190 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 72 | 0.190 |
Why?
|
| Trust | 1 | 2022 | 73 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2022 | 54 | 0.190 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 455 | 0.190 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 48 | 0.180 |
Why?
|
| Emergency Service, Hospital | 3 | 2025 | 1101 | 0.180 |
Why?
|
| Propensity Score | 2 | 2014 | 160 | 0.180 |
Why?
|
| Sentinel Surveillance | 3 | 2025 | 19 | 0.180 |
Why?
|
| Brain Injuries | 1 | 2003 | 140 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 209 | 0.170 |
Why?
|
| Work | 1 | 2020 | 15 | 0.170 |
Why?
|
| Telecommunications | 1 | 2020 | 9 | 0.170 |
Why?
|
| Heart | 1 | 2003 | 283 | 0.170 |
Why?
|
| Contact Tracing | 1 | 2020 | 17 | 0.170 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 598 | 0.170 |
Why?
|
| Interleukin-6 | 4 | 2017 | 321 | 0.170 |
Why?
|
| Symptom Assessment | 1 | 2020 | 47 | 0.170 |
Why?
|
| Drug Therapy, Computer-Assisted | 2 | 2012 | 11 | 0.170 |
Why?
|
| Blood Glucose | 2 | 2008 | 484 | 0.160 |
Why?
|
| Risk Factors | 7 | 2020 | 5354 | 0.160 |
Why?
|
| Body Water | 1 | 2000 | 15 | 0.160 |
Why?
|
| Electric Impedance | 1 | 2000 | 36 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 435 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 761 | 0.160 |
Why?
|
| Electronic Health Records | 5 | 2023 | 361 | 0.160 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 94 | 0.160 |
Why?
|
| Optimism | 1 | 2019 | 5 | 0.160 |
Why?
|
| Databases, Factual | 5 | 2016 | 873 | 0.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2005 | 44 | 0.160 |
Why?
|
| Pulmonary Alveoli | 1 | 2019 | 41 | 0.160 |
Why?
|
| Survival Analysis | 8 | 2019 | 583 | 0.150 |
Why?
|
| Catheterization, Swan-Ganz | 3 | 2012 | 13 | 0.150 |
Why?
|
| Body Composition | 1 | 2000 | 152 | 0.150 |
Why?
|
| Interleukin-18 | 1 | 2019 | 74 | 0.150 |
Why?
|
| Enteral Nutrition | 3 | 2012 | 54 | 0.150 |
Why?
|
| Double-Blind Method | 9 | 2017 | 739 | 0.150 |
Why?
|
| Intubation, Intratracheal | 1 | 2021 | 202 | 0.150 |
Why?
|
| APACHE | 7 | 2019 | 43 | 0.150 |
Why?
|
| Patient Care Planning | 1 | 2019 | 83 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2020 | 288 | 0.150 |
Why?
|
| Environmental Exposure | 1 | 2020 | 218 | 0.150 |
Why?
|
| Triage | 2 | 2018 | 126 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2020 | 311 | 0.140 |
Why?
|
| Ganciclovir | 1 | 2017 | 18 | 0.140 |
Why?
|
| Hospitals, Community | 1 | 2018 | 71 | 0.140 |
Why?
|
| Inpatients | 1 | 2020 | 305 | 0.140 |
Why?
|
| Cross Infection | 2 | 2020 | 164 | 0.130 |
Why?
|
| Advance Directives | 1 | 2017 | 47 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 66 | 0.130 |
Why?
|
| Quality of Life | 2 | 2022 | 1229 | 0.130 |
Why?
|
| Time Factors | 7 | 2023 | 3768 | 0.130 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 91 | 0.130 |
Why?
|
| Insulin | 2 | 2012 | 686 | 0.130 |
Why?
|
| Glasgow Coma Scale | 1 | 1996 | 46 | 0.120 |
Why?
|
| Acute Disease | 4 | 2019 | 671 | 0.120 |
Why?
|
| Health Facility Size | 1 | 2015 | 16 | 0.120 |
Why?
|
| Sex Factors | 4 | 2012 | 978 | 0.120 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 19 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 43 | 0.120 |
Why?
|
| Stomach Ulcer | 1 | 1995 | 7 | 0.120 |
Why?
|
| Pulmonary Wedge Pressure | 3 | 2011 | 27 | 0.120 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2025 | 18 | 0.110 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 1996 | 91 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 246 | 0.110 |
Why?
|
| Central Venous Pressure | 2 | 2012 | 14 | 0.110 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 2576 | 0.110 |
Why?
|
| Truth Disclosure | 1 | 2015 | 57 | 0.110 |
Why?
|
| Water-Electrolyte Balance | 2 | 2011 | 15 | 0.110 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 5 | 0.110 |
Why?
|
| Immunization Schedule | 2 | 2025 | 18 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2010 | 44 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2014 | 137 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 2681 | 0.100 |
Why?
|
| Clostridium Infections | 1 | 2014 | 49 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 1995 | 191 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 127 | 0.100 |
Why?
|
| Ventilator Weaning | 2 | 2011 | 20 | 0.100 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 9 | 0.100 |
Why?
|
| Disease Progression | 4 | 2021 | 1172 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2015 | 289 | 0.100 |
Why?
|
| Decision Support Systems, Management | 1 | 2012 | 2 | 0.100 |
Why?
|
| Programming Languages | 1 | 2012 | 14 | 0.090 |
Why?
|
| Thromboplastin | 1 | 2012 | 6 | 0.090 |
Why?
|
| Respiratory Rate | 1 | 2012 | 15 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 216 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 772 | 0.090 |
Why?
|
| Computers | 2 | 2022 | 49 | 0.090 |
Why?
|
| Fever | 1 | 2012 | 66 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2010 | 240 | 0.090 |
Why?
|
| Brain Ischemia | 1 | 1996 | 419 | 0.090 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 317 | 0.090 |
Why?
|
| gamma-Linolenic Acid | 1 | 2011 | 16 | 0.090 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2011 | 16 | 0.090 |
Why?
|
| Oxygen | 2 | 2023 | 317 | 0.090 |
Why?
|
| Hospital Administration | 1 | 2012 | 43 | 0.090 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 31 | 0.090 |
Why?
|
| Albuterol | 1 | 2011 | 24 | 0.090 |
Why?
|
| Therapeutics | 1 | 1991 | 5 | 0.090 |
Why?
|
| Health Surveys | 1 | 2013 | 313 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 480 | 0.090 |
Why?
|
| International Classification of Diseases | 1 | 2012 | 136 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2012 | 104 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2020 | 777 | 0.090 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2011 | 34 | 0.090 |
Why?
|
| Antibodies | 1 | 2012 | 183 | 0.090 |
Why?
|
| Health Status | 2 | 2022 | 436 | 0.090 |
Why?
|
| Energy Intake | 1 | 2012 | 171 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2012 | 162 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2012 | 162 | 0.090 |
Why?
|
| Documentation | 2 | 2022 | 128 | 0.090 |
Why?
|
| Biological Products | 1 | 2012 | 96 | 0.080 |
Why?
|
| Self Report | 2 | 2023 | 375 | 0.080 |
Why?
|
| Heart Rate | 1 | 2012 | 322 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 489 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 105 | 0.080 |
Why?
|
| Pregnancy | 3 | 2005 | 2334 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 141 | 0.080 |
Why?
|
| Rhabdomyolysis | 1 | 1989 | 23 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 252 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2012 | 512 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 937 | 0.080 |
Why?
|
| Rupture, Spontaneous | 2 | 2005 | 21 | 0.080 |
Why?
|
| Vascular Resistance | 3 | 2003 | 48 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 418 | 0.080 |
Why?
|
| Pulmonary Artery | 2 | 1987 | 95 | 0.080 |
Why?
|
| Infusions, Intravenous | 4 | 2018 | 173 | 0.080 |
Why?
|
| RNA | 2 | 2023 | 423 | 0.080 |
Why?
|
| Cocaine | 1 | 1989 | 101 | 0.070 |
Why?
|
| Ethics | 1 | 1988 | 1 | 0.070 |
Why?
|
| Ethical Review | 1 | 1988 | 3 | 0.070 |
Why?
|
| Ethics Committees, Clinical | 1 | 1988 | 5 | 0.070 |
Why?
|
| Ethics Committees | 1 | 1988 | 9 | 0.070 |
Why?
|
| Embolism, Amniotic Fluid | 1 | 1988 | 1 | 0.070 |
Why?
|
| Castor Oil | 1 | 1988 | 2 | 0.070 |
Why?
|
| Internet | 1 | 2012 | 469 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2458 | 0.070 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 734 | 0.070 |
Why?
|
| Human Experimentation | 1 | 1988 | 32 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2018 | 298 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2021 | 2079 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 1654 | 0.070 |
Why?
|
| Ethics Committees, Research | 1 | 1988 | 32 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2010 | 768 | 0.070 |
Why?
|
| Professional Practice | 1 | 2008 | 24 | 0.070 |
Why?
|
| Biomedical Research | 2 | 2012 | 268 | 0.070 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 1987 | 4 | 0.070 |
Why?
|
| Meningism | 1 | 1987 | 2 | 0.070 |
Why?
|
| Psychoses, Alcoholic | 1 | 1987 | 2 | 0.070 |
Why?
|
| Qualitative Research | 3 | 2017 | 690 | 0.070 |
Why?
|
| Hydrocortisone | 2 | 2012 | 193 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 864 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2008 | 136 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 167 | 0.070 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2005 | 5 | 0.060 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2005 | 6 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2008 | 305 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2005 | 15 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2005 | 32 | 0.060 |
Why?
|
| Acetates | 1 | 2005 | 33 | 0.060 |
Why?
|
| Health | 1 | 1985 | 31 | 0.060 |
Why?
|
| Cholestasis | 1 | 2005 | 65 | 0.060 |
Why?
|
| Hematoma | 1 | 2005 | 80 | 0.060 |
Why?
|
| Indoles | 1 | 2005 | 110 | 0.060 |
Why?
|
| Mortality | 1 | 1985 | 160 | 0.050 |
Why?
|
| omega-N-Methylarginine | 1 | 2004 | 8 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2008 | 495 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 47 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 790 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 20 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2024 | 83 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2005 | 151 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 851 | 0.050 |
Why?
|
| Vascular Capacitance | 1 | 2003 | 2 | 0.050 |
Why?
|
| Cardiac Volume | 1 | 2003 | 7 | 0.050 |
Why?
|
| Programming, Linear | 1 | 2003 | 1 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2024 | 120 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 112 | 0.050 |
Why?
|
| Ventricular Function | 1 | 2003 | 22 | 0.050 |
Why?
|
| Ventricular Pressure | 1 | 2003 | 30 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 1985 | 283 | 0.050 |
Why?
|
| Trauma Severity Indices | 1 | 2003 | 34 | 0.050 |
Why?
|
| Cause of Death | 1 | 2004 | 221 | 0.050 |
Why?
|
| Diastole | 1 | 2003 | 91 | 0.050 |
Why?
|
| Immunization | 1 | 2023 | 133 | 0.050 |
Why?
|
| Viral Load | 1 | 2023 | 231 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 35 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 114 | 0.050 |
Why?
|
| Syndrome | 1 | 2022 | 180 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 21 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 276 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 37 | 0.050 |
Why?
|
| Language | 1 | 2023 | 150 | 0.050 |
Why?
|
| Insurance Claim Review | 2 | 2012 | 76 | 0.050 |
Why?
|
| Health Services Research | 1 | 2003 | 271 | 0.040 |
Why?
|
| Vaccination Coverage | 1 | 2021 | 8 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2003 | 308 | 0.040 |
Why?
|
| Heart Failure | 2 | 2021 | 913 | 0.040 |
Why?
|
| Health Facilities | 1 | 2021 | 43 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2012 | 15 | 0.040 |
Why?
|
| Research Design | 2 | 2018 | 574 | 0.040 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.040 |
Why?
|
| Jejunostomy | 1 | 2000 | 7 | 0.040 |
Why?
|
| Jejunum | 1 | 2000 | 14 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 53 | 0.040 |
Why?
|
| Jejunal Diseases | 1 | 2000 | 7 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 49 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 33 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 144 | 0.040 |
Why?
|
| Risk | 3 | 2005 | 377 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 149 | 0.040 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2012 | 62 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 165 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2001 | 169 | 0.040 |
Why?
|
| Alprostadil | 1 | 1999 | 6 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 393 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2019 | 41 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1380 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 107 | 0.040 |
Why?
|
| Antimalarials | 1 | 2020 | 124 | 0.040 |
Why?
|
| Psychotic Disorders | 1 | 2021 | 158 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 1999 | 68 | 0.040 |
Why?
|
| Accidents, Traffic | 1 | 2000 | 146 | 0.040 |
Why?
|
| Liposomes | 1 | 1999 | 105 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 753 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 1094 | 0.040 |
Why?
|
| Mental Competency | 1 | 2019 | 61 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 97 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 19 | 0.030 |
Why?
|
| Virus Activation | 1 | 2017 | 24 | 0.030 |
Why?
|
| Data Collection | 2 | 2012 | 383 | 0.030 |
Why?
|
| Drug Carriers | 1 | 1999 | 178 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 568 | 0.030 |
Why?
|
| Obesity | 1 | 2005 | 1235 | 0.030 |
Why?
|
| Advance Care Planning | 1 | 2017 | 62 | 0.030 |
Why?
|
| Biomarkers | 2 | 2012 | 1408 | 0.030 |
Why?
|
| Psychometrics | 1 | 2018 | 376 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2016 | 38 | 0.030 |
Why?
|
| Insurance, Health | 2 | 2011 | 152 | 0.030 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 1995 | 3 | 0.030 |
Why?
|
| Narration | 1 | 2016 | 51 | 0.030 |
Why?
|
| Perception | 1 | 2016 | 174 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1377 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2015 | 119 | 0.030 |
Why?
|
| Social Work | 1 | 2015 | 25 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2014 | 3 | 0.030 |
Why?
|
| Cardiac Output | 2 | 1991 | 28 | 0.030 |
Why?
|
| Patient Selection | 2 | 2005 | 490 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2014 | 41 | 0.030 |
Why?
|
| Liver Failure | 1 | 2014 | 18 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 65 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 916 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 419 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 108 | 0.030 |
Why?
|
| Hemorrhage | 2 | 2008 | 267 | 0.020 |
Why?
|
| Thrombomodulin | 1 | 2012 | 17 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2012 | 93 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2012 | 30 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 88 | 0.020 |
Why?
|
| Organ Dysfunction Scores | 1 | 2012 | 23 | 0.020 |
Why?
|
| Hematuria | 1 | 2012 | 21 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2013 | 206 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 102 | 0.020 |
Why?
|
| Stroke | 1 | 2021 | 1196 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 134 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2011 | 94 | 0.020 |
Why?
|
| Economics, Hospital | 1 | 2011 | 15 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2011 | 151 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 242 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2012 | 122 | 0.020 |
Why?
|
| Hospital Departments | 1 | 1990 | 12 | 0.020 |
Why?
|
| Anemia | 1 | 2012 | 127 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 724 | 0.020 |
Why?
|
| Surgery Department, Hospital | 1 | 1990 | 21 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 454 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2011 | 117 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2011 | 196 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 465 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2011 | 126 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2012 | 183 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 459 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1990 | 158 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2011 | 235 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1147 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1996 | 697 | 0.020 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1988 | 5 | 0.020 |
Why?
|
| Government | 1 | 1988 | 8 | 0.020 |
Why?
|
| Respiratory Dead Space | 1 | 2008 | 2 | 0.020 |
Why?
|
| Third-Party Consent | 1 | 1988 | 9 | 0.020 |
Why?
|
| Control Groups | 1 | 1988 | 12 | 0.020 |
Why?
|
| Fees and Charges | 1 | 1988 | 17 | 0.020 |
Why?
|
| Social Control, Formal | 1 | 1988 | 20 | 0.020 |
Why?
|
| Terminally Ill | 1 | 1988 | 16 | 0.020 |
Why?
|
| Federal Government | 1 | 1988 | 19 | 0.020 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1988 | 6 | 0.020 |
Why?
|
| Placebos | 1 | 1988 | 72 | 0.020 |
Why?
|
| Fetal Death | 1 | 1988 | 14 | 0.020 |
Why?
|
| Government Regulation | 1 | 1988 | 41 | 0.020 |
Why?
|
| Research Subjects | 1 | 1988 | 40 | 0.020 |
Why?
|
| Observation | 1 | 2008 | 30 | 0.020 |
Why?
|
| Random Allocation | 1 | 1988 | 199 | 0.020 |
Why?
|
| Animals | 1 | 2006 | 20663 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 1988 | 89 | 0.020 |
Why?
|
| Patient Care | 1 | 1988 | 80 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 137 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 1988 | 90 | 0.020 |
Why?
|
| Informed Consent | 1 | 1988 | 140 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 258 | 0.020 |
Why?
|
| Anuria | 1 | 1987 | 1 | 0.020 |
Why?
|
| Oliguria | 1 | 1987 | 1 | 0.020 |
Why?
|
| Patients | 1 | 1988 | 113 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 1988 | 124 | 0.020 |
Why?
|
| Pericardial Effusion | 1 | 1987 | 21 | 0.020 |
Why?
|
| Research | 1 | 1988 | 193 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 131 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 196 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 125 | 0.020 |
Why?
|
| Heart Diseases | 1 | 1988 | 218 | 0.020 |
Why?
|
| Heart Arrest | 1 | 1988 | 171 | 0.020 |
Why?
|
| Motivation | 1 | 1988 | 285 | 0.020 |
Why?
|
| Group II Phospholipases A2 | 1 | 2005 | 2 | 0.020 |
Why?
|
| Keto Acids | 1 | 2005 | 3 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1985 | 7 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 2005 | 15 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1987 | 150 | 0.010 |
Why?
|
| Drug Costs | 1 | 2005 | 56 | 0.010 |
Why?
|
| Europe | 1 | 2005 | 195 | 0.010 |
Why?
|
| Phosphates | 1 | 1985 | 93 | 0.010 |
Why?
|
| Probability | 1 | 1985 | 170 | 0.010 |
Why?
|
| Medical Records | 1 | 1985 | 137 | 0.010 |
Why?
|
| Software | 1 | 2008 | 389 | 0.010 |
Why?
|
| Inflammation | 1 | 2011 | 1147 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 608 | 0.010 |
Why?
|
| Patient Admission | 1 | 1985 | 198 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 331 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2003 | 58 | 0.010 |
Why?
|
| Forecasting | 1 | 2003 | 232 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2001 | 13 | 0.010 |
Why?
|
| Splenectomy | 1 | 2000 | 42 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2000 | 69 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2000 | 124 | 0.010 |
Why?
|
| Models, Biological | 1 | 1985 | 1180 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 143 | 0.010 |
Why?
|
| Pancreas | 1 | 2000 | 151 | 0.010 |
Why?
|
| Massachusetts | 1 | 1985 | 2075 | 0.010 |
Why?
|
| Hypoxia | 1 | 1999 | 115 | 0.010 |
Why?
|
| Neoplasms | 1 | 2008 | 1364 | 0.010 |
Why?
|
| Pressure | 1 | 1987 | 79 | 0.000 |
Why?
|
| Abdomen | 1 | 1987 | 91 | 0.000 |
Why?
|